Mereo BioPharma Group Stock (NASDAQ:MREO)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$4.09

52W Range

$1.86 - $5.02

50D Avg

$4.30

200D Avg

$3.75

Market Cap

$655.41M

Avg Vol (3M)

$757.04K

Beta

0.97

Div Yield

-

MREO Company Profile


Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

33

IPO Date

Apr 24, 2019

Website

MREO Performance


MREO Financial Summary


Dec 23Dec 22Dec 21
Revenue$10.00M$1.51M$36.46M
Operating Income$-28.42M$-43.57M$-20.94M
Net Income$-29.47M$-34.20M$12.72M
EBITDA$-28.42M$-42.06M$-20.31M
Basic EPS-$-0.28$0.10
Diluted EPS-$-0.28$-0.25

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
XFORX4 Pharmaceuticals, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
HOOKHOOKIPA Pharma Inc.
TERNTerns Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
EFTReFFECTOR Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
HEPAHepion Pharmaceuticals, Inc.
ELEVElevation Oncology, Inc.
AMLXAmylyx Pharmaceuticals, Inc.